Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Fluorouracil + Tanibirumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 11||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Tanibirumab||TTAC-0001||VEGFR2 Antibody 4||Tanibirumab (TTAC-0001) is a monoclonal antibody directed against KDR (VEGFR2), which may inhibit tumor angiogenesis (PMID: 21910042).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Fluorouracil + Tanibirumab||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Tanibirumab (TTAC-0001) and Adrucil (fluorouracil) demonstrated enhanced inhibition of angiogenesis and tumor growth in colorectal cancer cell line xenograft models compared to either agent alone (PMID: 26325365).||26325365|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|